Introduction
We have recently described the controlled release of a protein (insulin) from a polymer using light. [1] The aim of such a material is to create what we call a Photoactivated Depot, or PAD. We envision such materials as being an effective way of controlling insulin release in response to blood sugar information. A PAD material can be injected intradermally, and then be stimulated to release insulin via transcutaneous irradiation. Because insulin is required in small but highly variable amounts, such a depot could eliminate the majority of injections while allowing for minute by minute adjustment of blood sugar through minute by minute variation of insulin release. As such, they can be an effective delivery component of an artificial pancreas. [2] [3] [4] [5] Our first described material used an insoluble polymer, linked to insulin using a photocleavable linker. The purpose of the polymer is to keep the insulin insoluble and at the injection site prior to irradiation. The insulin remains inert, until light breaks insulin's bond with the polymer, allowing it to be absorbed into systemic circulation. One of the key design requirements of such materials is density, i.e., the proportion of the material that is insulin. Density increases the lifetime of the depot and increases the rate of insulin release. Using a polymer base however reduces this density because the large majority of the atoms in the material are contained within the polymer, not the insulin. In this work, we explore an intriguing possibility, namely that the polymer itself could be formed using the protein, insulin, as a monomer, copolymerized with low molecular weight, photocleavable linkers. The resultant "macropolymers" could achieve dry weight efficiencies approaching 90%.
We have achieved this aim, using three monomer species in the polymerization: insulin monoazide (insulin with a single photocleavable, azide-terminated group attached), insulin diazide (insulin with two photocleavable, azide-terminated groups attached) and TD (for tris-DBCO a linker with three strained octyne DBCO groups that can react with and crosslink the azide containing protein monomers). We demonstrate that this polymer is effi ciently synthesized via MS and gel analysis. We then show that it is insoluble in buffer and photolyzes to release insulin and a small amount of residual linker.
. Results and Discussion
For the ultimate synthesis of the target macropolymer, we require the three species indicated in Scheme 1 , namely insulin monoazide (IMA), insulin diazide (IDA), and the linker TD. Depending on the ratio of these three species, we expected to form different species. For example, a ratio of 3:1 IMA:TD should predominantly give the simple trimer shown. A ratio of 1:1:1 IMA:IDA:TD should give a random mixture of larger oligomers and polymers as shown. Other ratios could lead to closed polyhedra with interesting properties.
We have previously described the synthesis of IMA and IDA. [ 1 ] These were formed upon the reaction of the precursor diazo-DMNPE-azide (DDA) with insulin, resulting in two main peaks upon HPLC analysis. We originally demonstrated by MS that these two peaks were IMA and IDA, respectively. Subsequently, with better chromatography, we have demonstrated that these "single" peaks are in fact a collection of closely related isomers, each consistent with IMA (in the fi rst cluster) or IDA (in the second cluster) ( Figure S1 -S5, Supporting Information). This is to be expected, as the diazo moiety of DDA can react with any of the six carboxyl groups found in insulin. Therefore there are six possible IMA and 15 possible IDA isomers. We use the entire cluster of singly modifi ed species as "IMA" and the entire cluster of doubly modifi ed species as "IDA." The new linker molecule TD was synthesized by condensation of cyclohexane tri-carboxylic acid with the strained octyne amine DBCO. [6] [7] [8] This structure and purity was confi rmed by NMR, MS, and HPLC ( Figures S6-10, Supporting Information) .
Early View
For the fi rst and simplest demonstration of reaction of TD with an insulin-azide, we synthesized the trimer. This was synthesized by reacting a 3.3:1 ratio of the IMA:TD in DMSO. The resulting material gave a cluster of three bands with the smallest species (with lowest intensity) consistent with the insulin standard ( Figure 1 ). We interpret the middle band, equidistant from the lower and upper bands, to be the doubly reacted species, and the highest (and major band) being the expected trimer. This sample gave a MS showing the trimer as the major product and the doubly reacted species as a minor product (Expected We then photolyzed this material in DMSO to demonstrate the release of insulin as a result of photolysis. The trimer was completely soluble in DMSO, as were the reaction products. We used a 365 nm centered Blak-Ray light source for this irradiation, and analyzed the products by PAGE (Figure 1 ). These show an interconversion of the higher band to the lower bands, ultimately resulting in a majority of insulin being formed. We analyzed the fi nal time point by ESI-MS and confi rmed that this was insulin ( Figure 1 ). The bands at each time point were quantitated using Photoshop, and then plotted ( Figure 2 plots are well fi tted by the equations for two sequential fi rst-order reactions, as would be expected from photolysis events (equations based on work by Benson). [ 9 ] There are actually three fi rst-order reactions expected, but the fi nal conversion of insulin with a single TD attached to insulin is "silent" because both species have the same mobility under the gel conditions used. Details of the kinetic scheme and fi tting can be found in the Supporting Information. The rate of trimer photolysis is ≈10 fold higher than observed previously for insulin diazide photolysis. This is likely due to the difference in solvent used during the photolysis (water with insulin diazide in the previous work, and DMSO with the trimer in the current work). DMSO was used for trimer photolysis because the trimer has low solubility in water. We then synthesized the polymer using a 1:1:1 ratio of IMA:IDA:TD, again in DMSO. The resulting products were analyzed using PAGE electrophoresis and samples loaded in a 1:1 mixture of DMSO:loading buffer, in which they were soluble (Figure 3 ). At time 0 we see multiple bands, including species similar to those seen in the trimer. In addition we see a series of higher bands going progressively up the gel to higher molecule weight, ultimately ending in a "smear." Insulin alone (i.e., without azide functionalities attached), identically treated, shows only a single band on the gel as expected, and so we interpret the reaction product bands as being increasing size oligomers and at the extreme end of the gel, polymers of insulin. It is interesting to note that the second band from the bottom, interpreted as two insulins attached to TD is particularly intense. We speculate that this is due to a second azide group on a 1:1:1 IMA:IDA:TD adduct "looping" back to react with the free DBCO valence on the TD. We would expect that this looped back adduct will quench polymerization. It may be possible to suppress this by modifying the arm length (and fl exibility) on the IMA, IDA, and or TD molecules. We determined from gel quantitation that insulin 2-8 mers constitute 80% of the products, where 9 mers and higher constitute 20% of the products. While our initial aim was a greater proportion of higher molecular weight species, the material as synthesized has the key properties that we seek, namely insolubility prior to irradiation followed by release of native insulin after irradiation.
To demonstrate that the polymeric material can be photolytically converted to insulin, we irradiated it using the 365 nm Blak Ray lamp, again in DMSO where it, and the products are completely soluble. During photolysis, we observe the higher molecular weight bands being progressively converted to lower molecular weight bands, until ultimately at the 20 min time point, we observe approximately complete conversion to insulin. We again confi rmed that the material in this band was insulin by ESI-MS analysis of the fi nal time point (Figure 3 ) .
The study described above was performed in DMSO to allow for the analysis of the products formed, and to demonstrate the interconversion of higher molecular weight species into insulin by irradiation over time. DMSO effectively solubilizes both insulin and its higher oligomers, allowing for direct visualization on gel analysis, however it is possible that the highest molecular weight materials are not as visible in the gel analysis due to reduced solubility. As effective as DMSO is at facilitating analysis of the polymerization products and photolysis products, it is not representative of the real world and long-term application of these materials. The purpose of these materials is to be initially insoluble in aqueous solution (at the site of insulin depot injection), and then to release soluble insulin in response to light.
To test this potential, we analyzed the polymeric material in phosphate buffered saline (PBS) instead of DMSO. In contrast to DMSO, the polymer was completely insoluble in PBS. We confi rmed this with two methods of analysis of the supernatant above the polymer, silver-stained PAGE gel analysis, and ELISA analysis. Both showed no detectable insulin in the supernatant above the material (Figures 4 and 5 ) prior to irradiation. We then irradiated the sample, using a 365 nm LED (Nichia), a source that is more intense than the Blak-ray lamp. We have found that inhomogeneous photolysis of insoluble materials (such as the polymeric material here, or previously studied resin bound insulin) require greater intensity light to effect photolysis.
With both gel and ELISA analysis, we demonstrate insulin being released into the supernatant. The ELISA analysis appears more sensitive, able to capture the very earliest release of insulin. The 55 min point represents in absolute terms a release of 4.7% of the total insulin contained in the material. a lag observed in insulin release, which is to be expected as initial photolytic events cleave some bonds that do not release insulin, but rather break the polymer into smaller, but still insoluble pieces. With time, the rate of release increases, as these smaller pieces are further photolyzed to form insulin. The ELISA analysis also demonstrates that polymeric material that is not irradiated, but is otherwise identically treated shows no release of insulin, confi rming the photolytic nature of the release process ( Figure 4 ) . A positive ELISA signal with irradiated samples also supports that insulin remains in a native conformation, as it is still recognized by two distinct antibodies after photolysis. The gel analysis ( Figure 5 ) parallels the ELISA results, showing low or undetectable insulin release at early time points, followed by increasing amounts with increased irradiation. For a point of comparison, we also loaded solubilized polymeric material onto the gel, solubilized using 1:1 DMSO:loading buffer. It is interesting to observe that in addition to the insulin band, two higher bands are also seen during photolysis. These may be the smallest pieces of the polymer that are soluble after photolysis or another Early View Publication; these are NOT the final page numbers, use DOI for citation !! unknown species. Their solubility may be increased in this experiment because of heating due to the intensity of the LED light source. When desalted and analyzed by ESI-MS, the combined time points indicate a mass of 5809, confi rming that it is insulin ( Figure 5 ) being released. No readily detected higher molecular weight species are found in the mass spectrum.
. Conclusions
In this work, we have demonstrated the feasibility of making new polymeric materials that release proteins in response to light, by using the proteins themselves as monomers, linked by small light cleaved linkers. These materials relate to prior work involving click chemistry, photosensitive polymers, and telechelic polymers. [ 2, [10] [11] [12] [13] [14] [15] [16] [17] [18] For the purposes of creating a photoactived insulin depot, the new materials approach ideality. The resinbound approach we previously described utilized an inert polymer, linked to insulin via a light-sensitive linker. As such, the effi ciency of the material was very low, with <5% dry weight being insulin, and the remainder being the polymer (needed to keep the insulin insoluble at the site of injection). With the macropolymer approach described herein, ≈85% of the dry weight of the material is insulin. This is because the insulin itself is the predominant mono mer that makes the polymer. Insulin density is key for three reasons: It increases the potential lifetime of a given injection volume, it reduces the total volume needed to provide an effective dose, and fi nally, it reduces the amount of light that needs to access the depot (by increasing the density of photolytically active sites). In addition to density, this material has three features that are key for its effectiveness as an insulin depot. It is completely insoluble in aqueous solution prior to irradiation, and then releases soluble insulin effi ciently in response to light. In addition it is completely "biodegradable," in so far as the consumption of the depot leaves only small, diffusible linkers after photolysis. The combination these attributes, make light sensitive macropolymers of insulin an ideal starting point for the creation of effi cient photoactivated insulin depots. In addition, the approach should allow for the release of any protein from a highly effi cient and dense material in a light-controlled manner.
. Experimental Section
(Complete materials and methods including NMR, MS, and HPLC results can be found in the Supporting Information).
Acetovanillone, t-butyl bromoacetate, nitric acid, 11-azido-3,6,9-trioxaundecan-1-amine, magnesium sulfate, hydrazine, manganese dioxide, molecular sieves, 1,3,5-Cyclohexanetricarboxylic acid (cis 95%), and human recombinant insulin were purchased from Sigma-Aldrich. DMSO and DMF were stored over molecular sieves containing glass vial and used as stated. DMF, DMSO, DCM, acetonitrile, methanol, ethanol, ethyl acetate, sodium chloride, potassium carbonate, trifl uoroacetic acid, acetic anhydride, 1 N HCl, diethyl ether, sodium bicarbonate, Celite545, 10× SDS PAGE running buffer were purchased from Fisher Scientifi c. DBCO amine (Click Chemistry Tools), hydroxybenzotrizole hydrate (Peptide International), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Calbiochem), Spin-X UF 5K NMWL membrane (Corning), Flat bottom glass vial insert 100 μL, diameter 3.4 mm (inner), 4.5 mm (outer), height 30.5 mm (Agilent, 5183-2090), Criterion TGX Any Kd precast gel (Bio-rad), Silver stain kit (Pierce), polypropylene white 96-well plate (BD Falcon), ultrasensitive human insulin ELISA kit (Alpco).
High-fi eld NMR was performed for 1H (400 MHz) or 13C (100 MHz) in d6-DMSO (99.9% atom D) containing 0.03%-1% v/v TMS using a Varian Inova 400 MHz NMR. UV-vis analysis was performed using a USB-2000 fi ber optic spectrometer (Ocean Optics, Inc.) with DT-Mini-B lamp source. HPLC analysis was performed using a modular Hewlett Packard Agilent 1050 series with attached vacuum degasser, auto sampler and diode array detector. C18 Hypersil (5 μm, 100 × 4.6 mm, Varian) column was used as stated in the method. For HPLC purifi cation C18 (5 μm, 250 × 10 mm, Phenomenex) column was used. HPLC-MS and MS-infusion analysis was performed using Q-Trap 3200 (ABI). The polyacrylaminde gel was run on Criterion vertical midiformat electrophoresis cell (Bio-rad) at 150 v. fi ltered through Celite 545 using glass-wool/glass-pipette. This celite pad was washed multiple times with total of 1062 μL of DMSO. Human recombinant insulin (100.8 mg, 17.35 μmoles) was dissolved in 7.1 mL anhydrous DMSO. The freshly prepared diazo-DMNPE-azide (DDA) was added to insulin solution and gently shaken for 24 h protecting it from light. The mixture was freeze dried and reconstituted in 0.01 N HCl. The sample was then fi ltered and washed twice with 0.01 N HCl using a spin fi lter (Corning Spin-X UF 500 concentrator) by following manufacturer's protocol. This was to remove excess reagents, while retaining the caged insulin products. The mixture was recovered from the fi lter by dissolving in 0.01 N HCl. Insulin monoazide and insulin diazide were purifi ed by using reversed-phase HPLC. Reversed-phase HPLC (fl ow rate 2 mL min −1 , runtime 45 min with 5 min post-run) solvent A (0.1% TFA in H2O), solvent B (0.1% TFA in acetonitrile (ACN)), gradient 0% B to 70% B over 45 min, C18 Hypersil column (5 μm, 250 × 10 mm, Phenomenex), relative yield (%); insulin (45.9%) monoazide insulin (40.7%); diazide insulin (13.3%). It was purifi ed multiple times to prepare in bulk and appropriate fractions were combined. After freeze drying it was reconstituted in DMSO to make fi nal stock solutions. 
. Preparation of Insulin Monoazide and Insulin Diazide

Synthesis of Tris-DBCO
Synthesis of Insulin Polymer
19.15 μL of Insulin monoazide (145 nmoles), 16 .86 μL of insulin diazide (145 nmoles) were mixed and added to 16.11 μL of TD (140 nmoles). All stock solutions were in DMSO. The reaction was allowed to go for 48 h at 37 °C in the dark. This stock was used for further studies of insulin polymer.
Photolysis Using the Lamp
Photolysis of Insulin Trimer
3.85 μL of insulin trimer mixture (described above) was diluted up to 35 μL in DMSO. The photolysis was done in polypropylene 96-well plate (BD Falcon) using a Blak-Ray lamp (Model XX-15L, 30 watts) source at a distance of 10 cm, the plate was irradiated from the top. At each time point, the irradiation was stopped and 5 μL volume from the mixture was withdrawn. Each time point was analyzed by running SDS-PAGE. The Criterion vertical midi-format electrophoresis system and Criterion TGX Any Kda precast gel was run according to manufacturer's instructions at 150 v for 50 min. The Coommassie blue was the staining dye. The final point was also analyzed by mass spec infusion. ESI−MS (m/z): [M] calculated for, insulin, 5808; found 5807.
Photolysis of Insulin Polymer
6.26 μL of insulin polymer stock was diluted up to 45 μL using DMSO. The photolysis was performed in the identical conditions described earlier using the lamp. At each time point, the irradiation was stopped and 5 μL solution was withdrawn. The samples were run on SDS-PAGE and stained using Coommassie blue. The final time point at 20 min was also analyzed by mass spec infusion. ESI−MS (m/z): [M] calculated for, insulin, 5808; found, 5807.
Photolysis Using the LED
Photolysis of Insulin Polymer in Buffer
11.86 μL of insulin polymer stock solution was added to two flat bottom glass vial insert each and freeze dried to remove DMSO. The residue was suspended in 110 μL of PBS. The photolysis was performed using a Nichia 200 mW 365 nm LED source at a distance of 0.5 mm, the vial was irradiated from the bottom. At each time point the irradiation was stopped, the suspension was vortexed, 55 μL supernatant was removed and replaced with the same volume of fresh PBS. The ELISA was performed to determine the concentration of released insulin. The solution was diluted appropriately in zero concentration standard provided with the kit. The samples were run on the gel as described earlier. The staining was performed using silver staining kit (Pierce). For the ESI-MS analysis, all the samples were combined and desalted using 5 kDa MWCO spin filter and infused; [M] calculated for, insulin, 5808; found, 5809.
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